Boundless Bio：FDA接受BBI-940驱动蛋白降解剂的IND申请

FDA于2026年1月接受了BBI-940的IND申请，使KOMODO-1首次人体试验能够在ER+/HER2-和TNBC-LAR乳腺癌患者中开放入组。公司目前拥有活跃的临床项目，现金储备可维持至2028年下半年，覆盖预期的初步概念验证数据读出。

关键事实

申报时间: 2026年3月9日 11:05
事件: 申请已受理
方向: 积极
公司: BOLDBoundless Bio, Inc.
资产: BBI-940
来源: SEC 8-K
可信度: 有来源

来源摘录

EX-99.1 2 bold-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited

SEC 8-K